FDA Grants Breakthrough Therapy Designation for Tucatinib in HER2-Positive Breast Cancer
Seattle Genetics announced the development after data was presented at the 2019 San Antonio Breast Cancer Symposium.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news